{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:03:11Z","timestamp":1788832991160,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa167","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T06:24:57Z","timestamp":1591770297000},"source":"Crossref","is-referenced-by-count":15,"title":["Coccidioidomycosis in Patients Treated With Ruxolitinib"],"prefix":"10.1093","volume":"7","author":[{"given":"Yael","family":"Kusne","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Kimes","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionna F","family":"Feller","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Patron","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Gea","family":"Banacloche","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis E","family":"Blair","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holenarasipur R","family":"Vikram","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M","family":"Ampel","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"2020061002243032200_CIT0001","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/23744235.2017.1390248","article-title":"Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature","volume":"50","author":"Dioverti","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"2020061002243032200_CIT0002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"2020061002243032200_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6807a1","article-title":"Surveillance for coccidioidomycosis - United States, 2011\u20132017","volume":"68","author":"Benedict","year":"2019","journal-title":"MMWR Surveill Summ"},{"key":"2020061002243032200_CIT0004","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/mmy\/myy019","article-title":"Coccidioidomycosis in selected immunosuppressed hosts","volume":"57","author":"Blair","year":"2019","journal-title":"Med Mycol"},{"key":"2020061002243032200_CIT0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archinte.1982.00340160069017","article-title":"Coccidioidomycosis in renal replacement therapy","volume":"142","author":"Cohen","year":"1982","journal-title":"Arch Intern Med"},{"key":"2020061002243032200_CIT0006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/lt.24055","article-title":"Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area","volume":"21","author":"Kahn","year":"2015","journal-title":"Liver Transpl"},{"key":"2020061002243032200_CIT0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2020061002243032200_CIT0008","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020061002243032200_CIT0009","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1093\/mmy\/myy146","article-title":"A review of innate and adaptive immunity to coccidioidomycosis","volume":"57","author":"Hung","year":"2019","journal-title":"Med Mycol"},{"key":"2020061002243032200_CIT0010","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/6\/ofaa167\/33373710\/ofaa167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/6\/ofaa167\/33373710\/ofaa167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T06:25:01Z","timestamp":1591770301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa167\/5840741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa167","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,5,19]]},"article-number":"ofaa167"}}